Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice.
Donor-derived fungal infections can be associated with serious complications in transplant recipients. Most cases of donor-derived candidiasis have occurred in kidney transplant recipients in whom contaminated preservation fluid is a commonly proposed source. Donors with cryptococcal disease, including those with unrecognized cryptococcal meningoencephalitis may transmit the infection with the allograft. Active histoplasmosis or undiagnosed and presumably asymptomatic infection in the donor that had not resolved by the time of death can result in donor-derived histoplasmosis in the recipient. Potential donors from an endemic area with either active or occult infection can also transmit coccidioidomycosis. Rare instances of aspergillosis and other mycoses, including agents of mucormycosis may also be transmitted from infected donors. Appropriate diagnostic evaluation and prompt initiation of appropriate antifungal therapy are warranted if donor-derived fungal infections are a consideration. This document discusses the characteristics, evaluation and approach to the management of donor-derived fungal infections in organ transplant recipients.
University of Pittsburgh, PA, USA. nis5@pitt.edu
N
N
Singh
S
S
Huprikar
S D
SD
Burdette
M I
MI
Morris
J E
JE
Blair
L J
LJ
Wheat
D000935:Antifungal Agents / Q000627:therapeutic use; D006801:Humans; D009181:Mycoses / Q000150:complications* / Q000188:drug therapy; D016377:Organ Transplantation; D017410:Practice Guidelines as Topic; D014019:Tissue Donors; D014481:United States
D000935:Antifungal Agents